CD47 and neoplasm: An important signal system is the CD47/signal regulatory protein alpha (SIRPα) pathway, which is the target for several inhibitory drugs that are currently being investigated in clinical trials including soluble variants of SIRPα to outcompete macrophage binding to CD47 on the tumor-cells [2].